Submitted:
12 August 2024
Posted:
14 August 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Participants
2.2. Cognitive Measures
2.2.1. SKT
2.2.2. MMSE
2.2.3. ACE-III
2.2.4. Data collection
2.2.5. Consensus Diagnoses
2.2.6. Comparing Group Status Across Measures
2.3. Statistical Analysis
3. Results
3.1. Sample Characteristics
3.2. Diagnostic Congruency
3.3. Sensitivity and Specificity
3.4. Concurrent Validity
4. Discussion
4.1. Limitations
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Nichols, E.; Steinmetz, J.D., Vollset, S.E., Fukutaki, K., Chalek, J., Abd-Allah, F,; Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T.T. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 2022, 7(2), e105-e125.
- Leifer, B.P. Early diagnosis of Alzheimer’s disease: Clinical and economic benefits. J. Am. Geriatr. Soc. 2003, 51, 281–288. [Google Scholar] [CrossRef] [PubMed]
- Dubois, B.; Padovani, A.; Scheltens, P.; Rossi, A.; Dell’Agnello, G. Timely Diagnosis for Alzheimer’s Disease: A Literature Review on Benefits and Challenges. J. Alzheimer’s Dis. 2016, 49, 617–631.
- Jeremic D, Navarro-López JD, Jiménez-Díaz L. Efficacy and safety of anti-amyloid-β monoclonal antibodies incurrent Alzheimer’s disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis. Ageing Res. Rev. 2023; 90:102012. [CrossRef]
- Sperling RA, Donohue MC, Raman R et al. Trial of Solanezumab in Preclinical Alzheimer’s Disease. N. Engl. J. Med. 2023 ;389(12),1096-1107.
- van Dyck CH, Swanson CJ, Aisen P, Bateman, R. J., Chen, C., Gee, M., ... & Iwatsubo, T. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. 2023;388(1), 9-21.
- Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., ... & Kaul, S. . Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. Jama 2023, 330(6), 512-527.
- Stemmler, M.; Lehfeld, H.; Erzigkeit, A. SKT. A Short Cognitive Performance Test according to Hellmut Erzigkeit. SKT English Manual Edition 2019; Geromed Publishing: Spardorf, Germany, 2019. [Google Scholar]
- Schneider, L.S. Rating Scales and Outcome Variables Used in Clinical Trials. In Alzheimer’s Disease: A Physician’s Guide to Practical Management; Richter, R.W., Richter, B.Z., Eds.; Humana Press: Totowa, NJ, USA, 2004; pp. 337–349. [Google Scholar]
- Kim Y. S., Nibbelink D. W. & Overall J.E. Factor structure and scoring of the SKT test battery. J. Clin. Psychol. 1993, 49(1),61-71.
- Hessler, J. B, Stemmler M., Horst, B. Cross-Validation of the Newly-Normed SKT for the Detection of MCI and Dementia. GeroPsych 2017, 30, 19–25. [Google Scholar] [CrossRef]
- Stemmler, M.; Hessler, J.B.; Bickel, H. Predicting Cognitive Decline and Dementia with the Newly Normed SKT Short Cognitive Performance Test. Dement. Geriatr. Cogn. Disord. Extra 2019, 9, 184–193. [Google Scholar] [CrossRef] [PubMed]
- Fornazzari, L.; Cumsille, F.; Quevedo, F.; Quiroga, P.; Rioseco, P.; Klaasen, G.; Martinez, C.G.; Rhode, G.; Sacks, C.; Rivera, E.; et al. Spanish validation of the Syndrom Kurztest (SKT). Alzheimer Dis. Assoc. Disord. 2001, 15, 211–215. [Google Scholar] [CrossRef] [PubMed]
- Skjerve, A., Nordhus, I. H., Engedal, K., Braekhus, A., Nygaard, H. A., Pallesen, S., & Haugen, P. K. Validation of the Seven Minute Screen and Syndrom Kurztest among elderly Norwegian outpatients. Int. Psychogeriatr. 2008, 20(4), 807-814.
- Bruno, D., & Schurmann Vignaga, S. Addenbrooke’s cognitive examination III in the diagnosis of dementia: a critical review. Neuropsychiatr. Dis. Treat. 2019, 441-447.
- Crawford, J. R., & Garthwaite, P. H. Comparing patients’ predicted test scores from a regression equation with their obtained scores: a significance test and point estimate of abnormality with accompanying confidence limits. Neuropsychology 2006, 20(3), 259.
- Urban, J., Scherrer, V., Strobel, A., & Preckel, F. Continuous norming approaches: A systematic review and real data example. Assessment, 2023, 10731911241260545.
- Stemmler, M., Schneider, S. M., & Poon, L. W. The application of the skt short cognitive performance test to english-speaking populations. Psych, 2021, 3(4), 717-727.
- Folstein, M.F.; Folstein, S.E.; McHugh, P.R. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12, 189–198. [Google Scholar] [CrossRef] [PubMed]
- Noone, P. Addenbrooke’s cognitive examination-III. Occup. Med. 2015, 65(5), 418–420. [Google Scholar] [CrossRef] [PubMed]
- Sachdev, P. S., Brodaty, H., Reppermund, S., Kochan, N. A., Trollor, J. N., Draper, B., ... & Memory and Ageing Study Team. The Sydney Memory and Ageing Study (MAS): methodology and baseline medical and neuropsychiatric characteristics of an elderly epidemiological non-demented cohort of Australians aged 70–90 years. Int. psychoger. 2010, 22(8), 1248-1264.
- Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. O., ... & Petersen, R. C. Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J. Int. Med, 2004, 256(3), 240-246.
- APA American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV (Vol. 4); American Psychiatric Pub Washington, DC, USA, 2000.
- APA American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®); American Psychiatric Pub: Washington, DC, USA, 2013. [Google Scholar]
- O. Spreen and A. L. Benton, Neurosensory Center Comprehensive Examination for Aphasia (NCCEA), University of Victoria, Victoria, Canada, 1977.
- Wechsler, D.; Coalson, D.L.; Raiford, S.E. WAIS-IV Technical and Interpretive Manual; Pearson: Boston, MA, USA, 2008.
- Sattler, J. M., & Ryan, J. J. Assessment with the WAIS-IV. Jerome M Sattler Publisher. 2009.
- Hsieh, S., Schubert, S., Hoon, C., Mioshi, E., & Hodges, J. R. Validation of the Addenbrooke’s Cognitive Examination III in frontotemporal dementia and Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 2013 36(3-4), 242-250.
- Ellison, J. M., Harper, D. G., Berlow, Y., & Zeranski, L. Beyond the “C” in MCI: noncognitive symptoms in amnestic and non-amnestic mild cognitive impairment. CNS Spect. 2008,13(1), 66-72.
- Salthouse, T. A. The processing-speed theory of adult age differences in cognition. Psychol. Rev. 1996, 103(3), 403. [Google Scholar] [CrossRef] [PubMed]
- Lu, Y., Hu, J., Stemmler, M., & Guo, Q. Validation of Chinese version of SKT (Syndrom Kurztest): a short cognitive performance test for the assessment of memory and attention. Diagnostics 21 11(12), 2253.
- Stemmler, M.; Lehfeld, H.; Siebert, J.; Horn, R. Ein kurzer Leistungstest zur Erfassung von Störungen des Gedächtnisses und der Aufmerksamkeit: SKT Manual Edition 2015–und der regressionsbasierte Ansatz [A brief performance test to assess impairment of memory and attention: SKT Manual Edition 2015-and the regression-based approach]. Diagnostica 2017, 63, 243–255. [Google Scholar]
- Kochhann, R., Varela, J. S., Lisboa, C. S. D. M., & Chaves, M. L. F. The Mini Mental State Examination: Review of cutoff points adjusted for schooling in a large Southern Brazilian sample. Dementia & neuropsychologia 2010 4, 35-41.
- Bartos, A., & Raisova, M. The Mini-Mental State Examination: Czech norms and cutoffs for mild dementia and mild cognitive impairment due to Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 2016, 42(1-2), 50-57.
- Matías-Guiu, J. A., Fernández-Bobadilla, R., Fernández-Oliveira, A., Valles-Salgado, M., Rognoni, T., Cortés-Martínez, A., … & Matías-Guiu, J. Normative data for the Spanish version of the Addenbrooke’s Cognitive Examination III. . Dement. Geriatr. Cogn. Disord. 2016, 41(5-6), 243-250.
- Ryan, J.J.; Sattler, J.M.; Lopez, S.J. Age effects on Wechsler Adult Intelligence Scale-III subtests. Arch. Clin. Neuropsychol. 2000, 15, 311–317. [Google Scholar] [CrossRef] [PubMed]
- Tombaugh, T. N., Kozak, J., & Rees, L. Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. Arch. Clin. Neuropsychol. 1999 ,14(2), 167-177.


| Wave 6 | Wave 7 | Total Number of Persons Used for Calculations | |
|---|---|---|---|
| Consensus Diagnosis | 33 | 78 | 111 |
| SKT | 34 | 106 | 140 |
| MMSE | 142 | 109 | 143 |
| ACE-III | 142 | 0 |
| N | min | max | mean | SD | |
|---|---|---|---|---|---|
| Age | 143 | 83 | 98 | 87.73 | 3.54 |
| Sex* | 143 | 0 | 1 | 0.63 | 0.49 |
| Years of Education | 143 | 6 | 24 | 12.63 | 3.46 |
| Digital Symbol Coding | 137 | 12 | 78 | 42.14 | 12.22 |
| F-A-S Test | 139 | 12 | 71 | 37.78 | 12.86 |
| SKT | 139 | 0 | 11 | 2.99 | 2.84 |
| ACE-III | 142 | 63 | 100 | 89.58 | 5.96 |
| MMSE | 143 | 24 | 30 | 28.87 | 1.41 |
| SKT |
Green (no cognitive impairment) N (%) |
Yellow (MCI) N (%) | Red (dementia) N (%) | ||
| Consensus Diagnosis | |||||
| No cognitive impairment | 58 (82.9) | 12 (17.1) | 0 (0) | 70 | |
| MCI | 4 (26.7) | 11 (73.3) | 0 (0) | 15 | |
| Dementia | 2 (12.5) | 12 (75) | 2 (12.5) | 16 | |
| Total | 64 | 35 | 2 | 101 | |
| Sensitivity | Specificity |
Area under the Curve | ||
|---|---|---|---|---|
| SKT |
no cognitive impairment vs. cognitive impairment |
80.6 | 82.9 | 87.5 |
| normal cognition vs. MCI | 73.3 | 82.9 | 88 | |
| MMSE |
no cognitive impairment vs. cognitive impairment |
21.2 | 97.1 | 63.7 |
|
normal cognition vs. MCI |
12.5 | 98.6 | 56.3 | |
| ACE-III |
no cognitive impairment vs. cognitive impairment |
70 | 84.1 | 83 |
| normal cognition vs. MCI | 72.7 | 86.6 | 83.7 |
| Consensus Diagnosis |
SKT | MMSE | ||
| SKT | 0.60** | |||
| MMSE | 0.32** | 0.24** | ||
| ACE-III | 0.54** | 0.32** | 0.34** |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).